Hsien-Yuan Lane

List of Publications by Year
in descending order

83	3,910	147801	128289
papers	citations	31	60
		h-index	g-index

84	84	84	3466
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 2004, 55, 452-456.	1.3	325
2	Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia. Archives of General Psychiatry, 2005, 62, 1196.	12.3	263
3	Add-on Treatment of Benzoate for Schizophrenia. JAMA Psychiatry, 2013, 70, 1267.	11.0	194
4	Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia. Biological Psychiatry, 2006, 60, 645-649.	1.3	182
5	Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study. Biological Psychiatry, 2008, 63, 9-12.	1.3	161
6	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 451.	2.1	159
7	Machine learning and systems genomics approaches for multi-omics data. Biomarker Research, 2017, 5, 2.	6.8	147
8	Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior, 2012, 100, 665-677.	2.9	132
9	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
10	Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry, 2014, 75, 678-685.	1.3	106
11	Brain Stimulation in Alzheimer's Disease. Frontiers in Psychiatry, 2018, 9, 201.	2.6	98
12	Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry, 2018, 84, 422-432.	1.3	95
13	d-glutamate and Gut Microbiota in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 2676.	4.1	86
14	Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 2761.	4.1	82
15	Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 723-739.	4.8	80
16	NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease. Current Neuropharmacology, 2012, 10, 272-285.	2.9	75
17	Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. World Journal of Biological Psychiatry, 2017, 18, 357-368.	2.6	72
18	Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Scientific Reports, 2017, 7, 14849.	3.3	71

#	Article	IF	Citations
19	Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches. International Journal of Molecular Sciences, 2020, 21, 969.	4.1	65
20	Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. International Journal of Molecular Sciences, 2021, 22, 8208.	4.1	62
21	Decreased mRNA expression for the two subunits of system xcˉ, SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: Evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. Journal of Psychiatric Research, 2016, 72, 58-63.	3.1	61
22	NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 5169-5179.	1.9	60
23	Assessing Gene-Gene Interactions in Pharmacogenomics. Molecular Diagnosis and Therapy, 2012, 16, 15-27.	3.8	58
24	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. Frontiers in Psychiatry, 2019, 10, 93.	2.6	51
25	Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design. Molecules, 2020, 25, 3250.	3.8	51
26	D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. Pharmacology Biochemistry and Behavior, 2019, 185, 172760.	2.9	50
27	Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease. Frontiers in Psychiatry, 2018, 9, 91.	2.6	40
28	Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 2283.	4.1	39
29	Evaluation of psychometric properties of the Chinese Mandarin version State‐Trait Anxiety Inventory Y form in Taiwanese outpatients with anxiety disorders. Journal of Psychiatric and Mental Health Nursing, 2013, 20, 499-507.	2.1	37
30	Genome-wide association studies in pharmacogenomics of antidepressants. Pharmacogenomics, 2015, 16, 555-566.	1.3	37
31	Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. International Journal of Molecular Sciences, 2021, 22, 2146.	4.1	36
32	Genetic Biomarkers on Age-Related Cognitive Decline. Frontiers in Psychiatry, 2017, 8, 247.	2.6	33
33	Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2019, 33, 436-448.	4.0	33
34	Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Molecular Psychiatry, 2014, 19, 636-637.	7.9	31
35	Combination of G72 Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches. Frontiers in Psychiatry, 2018, 9, 566.	2.6	30
36	The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. Frontiers in Pharmacology, 2019, 10, 540.	3.5	29

#	Article	IF	Citations
37	<p>Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 509-518.	2.2	29
38	Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biological Psychology, 2010, 83, 79-83.	2.2	28
39	Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia. JAMA Network Open, 2021, 4, e216156.	5.9	28
40	Acute Amino Acid <scp>d</scp>-Serine Administration, Similar to Ketamine, Produces Antidepressant-like Effects through Identical Mechanisms. Journal of Agricultural and Food Chemistry, 2017, 65, 10792-10803.	5.2	27
41	Gender‐Specific Differences in Susceptibility to Low‐Dose Methadone‐Associated QTc Prolongation in Patients with Heroin Dependence. Journal of Cardiovascular Electrophysiology, 2012, 23, 527-533.	1.7	26
42	Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7911.	4.1	26
43	An Investigation into Smartphone Addiction with Personality and Sleep Quality among University Students. International Journal of Environmental Research and Public Health, 2021, 18, 7588.	2.6	26
44	Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2020, 34, 495-505.	4.0	25
45	Plasma <scp>d</scp>-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches. Journal of Psychopharmacology, 2021, 35, 265-272.	4.0	24
46	Molecular Basis of Late-Life Depression. International Journal of Molecular Sciences, 2021, 22, 7421.	4.1	24
47	From Menopause to Neurodegeneration—Molecular Basis and Potential Therapy. International Journal of Molecular Sciences, 2021, 22, 8654.	4.1	24
48	Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial. International Journal of Neuropsychopharmacology, 2021, 24, 392-399.	2.1	23
49	Sensitivity and specificity of the Chinese version of the Schizotypal Personality Questionnaire-Brief for identifying undergraduate students susceptible to psychosis. International Journal of Nursing Studies, 2010, 47, 1535-1544.	5.6	21
50	The C-Terminal Region of G72 Increases D-Amino Acid Oxidase Activity. International Journal of Molecular Sciences, 2014, 15, 29-43.	4.1	21
51	An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways. Frontiers in Bioengineering and Biotechnology, 2020, 8, 569.	4.1	21
52	Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial. International Journal of Neuropsychopharmacology, 2022, 25, 545-555.	2.1	20
53	A model testing factors that influence physical activity for Taiwanese adults with anxiety. Research in Nursing and Health, 2008, 31, 476-489.	1.6	19
54	Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. Journal of Psychopharmacology, 2019, 33, 1030-1033.	4.0	19

#	Article	IF	Citations
55	Shifting From Haloperidol to Risperidone for Behavioral Disturbances in Dementia: Safety, Response Predictors, and Mood Effects. Journal of Clinical Psychopharmacology, 2002, 22, 4-10.	1.4	18
56	NMDA Pathology and Treatment of Schizophrenia. Current Pharmaceutical Design, 2014, 20, 5118-5126.	1.9	18
57	Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder. Journal of Affective Disorders, 2019, 245, 1119-1125.	4.1	17
58	Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study. Antioxidants, 2021, 10, 1839.	5.1	15
59	Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions. Scientific Reports, 2021, 11, 6922.	3.3	14
60	Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment. International Journal of Molecular Sciences, 2021, 22, 9718.	4.1	14
61	Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Current Drug Targets, 2020, 21, 610-615.	2.1	14
62	d-Amino Acids and pLG72 in Alzheimer's Disease and Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 10917.	4.1	14
63	pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase. Scientific Reports, 2019, 9, 13221.	3.3	13
64	Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments. Clinical Psychopharmacology and Neuroscience, 2021, 19, 577-588.	2.0	12
65	De Novo Peptide and Protein Design Using Generative Adversarial Networks: An Update. Journal of Chemical Information and Modeling, 2022, 62, 761-774.	5.4	12
66	Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience, 2021, 19, 423-433.	2.0	11
67	Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection. Scientific Reports, 2021, 11, 10179.	3.3	10
68	Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms. Pharmacology Biochemistry and Behavior, 2022, 213, 173335.	2.9	7
69	Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People With Mild Cognitive Impairment: A Two-Year Prospective Study. International Journal of Neuropsychopharmacology, 2022, 25, 660-665.	2.1	7
70	Effects of the Health-Awareness-Strengthening Lifestyle Program in a Randomized Trial of Young Adults with an At-Risk Mental State. International Journal of Environmental Research and Public Health, 2021, 18, 1959.	2.6	6
71	C-reactive protein is associated with severity of thought and language dysfunction in patients with schizophrenia . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2621-2627.	2.2	5
72	<p>Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 771-780.	2.2	5

#	Article	IF	Citations
73	Trough Melatonin Levels Differ between Early and Late Phases of Alzheimer Disease. Clinical Psychopharmacology and Neuroscience, 2021, 19, 135-144.	2.0	5
74	Risk Assessment for Heroin Use and Craving Score Using Polygenic Risk Score. Journal of Personalized Medicine, 2021, 11, 259.	2.5	5
75	Efficiency of an Online Health-Promotion Program in Individuals with At-Risk Mental State during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 11875.	2.6	4
76	Predicting Anticancer Drug Resistance Mediated by Mutations. Pharmaceuticals, 2022, 15, 136.	3.8	4
77	Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry. Molecules, 2021, 26, 4457.	3.8	3
78	Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning: A case series. Psychiatry and Clinical Neurosciences, 2019, 73, 348-348.	1.8	2
79	Benzoate treatment for adolescent anti-NMDAR encephalitis. Schizophrenia Research, 2020, 222, 472-473.	2.0	2
80	Suicide Ideation among Outpatients with Alcohol Use Disorder. Behavioural Neurology, 2022, 2022, 1-7.	2.1	2
81	Antihistamine promotes electroacupuncture analgesia in healthy human subjects: A pilot study. Journal of Traditional and Complementary Medicine, 2022, , .	2.7	1
82	In Reply: Trough Melatonin Levels Have No Physiological or Clinical Relevance. Clinical Psychopharmacology and Neuroscience, 2021, 19, 393-393.	2.0	0
83	Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment. Journal of Personalized Medicine, 2022, 12, 835.	2.5	0